Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways

References

• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• HermanJGLatifFWengYSilencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinomaProc Natl Acad Sci U S A19949121970097047937876
   PubMed Web of Science ®Google Scholar
• HannaSCHeathcoteSAKimWYmTOR pathway in renal cell carcinomaExpert Rev Anticancer Ther20088228329218279068
   PubMed Web of Science ®Google Scholar
• KaelinWGJrThe von Hippel-Lindau tumour suppressor protein: O2 sensing and cancerNat Rev Cancer200881186587318923434
   PubMed Web of Science ®Google Scholar
• DorđevićGMatušan IlijašKHadžisejdićIMaričićAGrahovacBJonjićNEGFR protein overexpression correlates with chromosome 7 polysomy and poor prognostic parameters in clear cell renal cell carcinomaJ Biomed Sci2012194022475688
   PubMed Web of Science ®Google Scholar
• SzymańskaKMooreLERothmanNTP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern EuropeCancer Lett20102931929820137853
   PubMed Web of Science ®Google Scholar
• HayNSonenbergNUpstream and downstream of mTORGenes Dev200418161926194515314020
   PubMed Web of Science ®Google Scholar
• PalSKHeMTongTRNA-seq reveals aurora kinase-driven mTOR Pathway activation in patients with sarcomatoid metastatic renal cell carcinomaMol Cancer Res201513113013725183163
   PubMed Web of Science ®Google Scholar
• BaileySTZhouBDamrauerJSmTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinomaPloS One201499e10441325180793
   PubMed Web of Science ®Google Scholar
• OkazakiHMatsunagaNFujiokaTCircadian regulation of mTOR by the ubiquitin pathway in renal cell carcinomaCancer Res201474254355124253377
   PubMed Web of Science ®Google Scholar
• GuertinDASabatiniDMDefining the role of mTOR in cancerCancer Cell200712192217613433
   PubMed Web of Science ®Google Scholar
• ChenHXiongTQuYZhaoFFerrieroDMuDmTOR activates hypoxia-inducible factor-1α and inhibits neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemiaNeurosci Lett2012507211812322178140
   PubMed Web of Science ®Google Scholar
• LandSCTeeARHypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motifJ Biol Chem200728228205342054317502379
   PubMed Web of Science ®Google Scholar
• ThomasGVTranCMellinghoffIKHypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNat Med200612112212716341243
   PubMed Web of Science ®Google Scholar
• KararJCernigliaGJLindstenTKoumenisCMaityADual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxiaCancer Biol Ther201213111102111122895065
   PubMed Web of Science ®Google Scholar
• DasteAGross-GoupilMRocaSBernhardJCRavaudAProlonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literatureTarget Oncol201491818423283668
   PubMed Web of Science ®Google Scholar
• SantoniMBerardiRAmantiniCRole of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitorInt J Cancer2014134122772277724114790
   PubMed Web of Science ®Google Scholar
• PanwalkarAVerstovsekSGilesFJMammalian target of rapamycin inhibition as therapy for hematologic malignanciesCancer2004100465766614770419
   PubMed Web of Science ®Google Scholar
• Meric-BernstamFGonzalez-AnguloAMTargeting the mTOR signaling network for cancer therapyJ Clin Oncol200927132278228719332717
   PubMed Web of Science ®Google Scholar
• HuangSHoughtonPJTargeting mTOR signaling for cancer therapyCurr Opin Pharmacol20033437137712901945
   PubMed Web of Science ®Google Scholar
• AtkinsMBHidalgoMStadlerWMRandomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomaJ Clin Oncol200422590991814990647
   PubMed Web of Science ®Google Scholar
• MohiMGBoultonCGuTLCombination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKsProc Natl Acad Sci U S A200410193130313514976243
   PubMed Web of Science ®Google Scholar
• MondesireWHJianWZhangHTargeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cellsClin Cancer Res200410207031704215501983
   PubMed Web of Science ®Google Scholar
• FeiSJZhangXCDongSTargeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cellsPloS One201387e6910423874880
   PubMed Web of Science ®Google Scholar
• KuBMKimDSKimKHTransglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinomaFASEB J20132793487349523704086
   PubMed Web of Science ®Google Scholar
• ZhuZXingSChengPThe relationship of expression of Bcl-2, p53, and proliferating cell nuclear antigen (PCNA) to cell proliferation and apoptosis in renal cell carcinomaJ Huazhong Univ Sci Technolog Med Sci200424435435715587397
   PubMedGoogle Scholar
• MiyakeHHaraIGohjiKArakawaSKamidonoSp53 Modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell lineInt J Oncol19981224694739458377
   PubMed Web of Science ®Google Scholar
• de RozieresSMayaROrenMLozanoGThe loss of mdm2 induces p53-mediated apoptosisOncogene200019131691169710763826
   PubMed Web of Science ®Google Scholar
• GrossmanSRPerezMKungALp300/MDM2 complexes participate in MDM2-mediated p53 degradationMol Cell1998244054159809062
   PubMed Web of Science ®Google Scholar
• MomandJZambettiGPOlsonDCGeorgeDLevineAJThe mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell1992697123712451535557
   PubMed Web of Science ®Google Scholar
• OlinerJDPietenpolJAThiagalingamSGyurisJKinzlerKWVogelsteinBOncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature199336264238578608479525
   PubMed Web of Science ®Google Scholar
• JinLTabeYKojimaKMDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphomaCancer Lett2010299216117020850924
   PubMed Web of Science ®Google Scholar
• YuHZouYJiangLInduction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticlesBiomaterials201334112738274723352573
   PubMed Web of Science ®Google Scholar
• MirRTortosaAMartinez-SolerFMdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cellsInt J Cancer201313271525153622961628
   PubMed Web of Science ®Google Scholar
• KongLYuanQZhuHThe suppression of prostate LNCaP cancer cells growth by selenium nanoparticles through Akt/Mdm2/AR controlled apoptosisBiomaterials201132276515652221640377
   PubMed Web of Science ®Google Scholar
• NoonAPVlatkovicNPolanskiRP53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?Cancer2010116478079020052733
   PubMed Web of Science ®Google Scholar
• UchidaTGaoJPWangCClinical significance of p53, mdm2, and Bcl-2 proteins in renal cell carcinomaUrology200259461562011927338
   PubMed Web of Science ®Google Scholar
• HaitelAWienerHGBaethgeUMarbergerMSusaniMMdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parametersClin Cancer Res2000651840184410815906
   PubMed Web of Science ®Google Scholar
• KojimaKShimanukiMShikamiMThe dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AMLLeukemia20082291728173618548093
   PubMed Web of Science ®Google Scholar
• MohammadRMWuJAzmiASAn MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animalsMol Cancer2009811519958544
   PubMed Web of Science ®Google Scholar
• HirataHHinodaYKikunoNMDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinomaClin Cancer Res200713144123412917634539
   PubMed Web of Science ®Google Scholar
• LinFZhangPLYangXJPrichardJWLunMBrownREMorphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomasAnn Clin Lab Sci200636328329316951269
   PubMed Web of Science ®Google Scholar
• FuldaSSynthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signalingMitochondrion201419Pt A858724780492
   PubMedGoogle Scholar
• MinetEMichelGRemacleJMichielsCRole of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (review)Int J Mol Med20005325325910677565
   PubMed Web of Science ®Google Scholar
• KaoCLHsuHSChenHWChengTHRapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cellsCancer Lett2009286225025919560264
   PubMed Web of Science ®Google Scholar
• FengZZhangHLevineAJJinSThe coordinate regulation of the p53 and mTOR pathways in cellsProc Natl Acad Sci U S A2005102238204820915928081
   PubMed Web of Science ®Google Scholar
• FengZLevineAJThe regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 proteinTrends Cell Biol201020742743420399660
   PubMed Web of Science ®Google Scholar
• von RoemelingCAMarlowLAKennedyWPKennedyGTCoplandJAMenefeeMEPreclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinomaAm J Cancer Res20133439040123977448
   PubMed Web of Science ®Google Scholar
• RoulinDWaselleLDormond-MeuwlyADufourMDemartinesNDormondOTargeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenibMol Cancer2011109021791089
   PubMed Web of Science ®Google Scholar
• HollandWSTepperCGPietriJEEvaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapyCancer Chemother Pharmacol201269118519421644050
   PubMed Web of Science ®Google Scholar
• ChoyMKMovassaghMBennettMRFooRSPKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2J Cell Physiol2010222363563919950214
   PubMed Web of Science ®Google Scholar
• ZuckermanVWolyniecKSionovRVHauptSHauptYTumour suppression by p53: the importance of apoptosis and cellular senescenceJ Pathology20092191315
   PubMed Web of Science ®Google Scholar
• SantoniMPantanoFAmantiniCEmerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinomaBiochim Biophys Acta20141845222123124480319
   PubMed Web of Science ®Google Scholar
• GemmillRMZhouMCostaLKorchCBukowskiRMDrabkinHASynergistic growth inhibition by Iressa and rapamycin is modulated by VHL mutations in renal cell carcinomaBr J Cancer200592122266227715956968
   PubMed Web of Science ®Google Scholar
• MaiuriMCGalluzziLMorselliEKeppOMalikSAKroemerGAutophagy regulation by p53Curr Opin Cell Biol201022218118520044243
   PubMed Web of Science ®Google Scholar
• TasdemirEMaiuriMCGalluzziLRegulation of autophagy by cytoplasmic p53Nat Cell Biol200810667668718454141
   PubMed Web of Science ®Google Scholar